Bristol-Myers Squibb Company (BMY) : During the past 4 weeks, traders have been relatively bearish on Bristol-Myers Squibb Company (BMY), hence the stock is down -4.29% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.64% relative to the S&P 500. The 4-week change in the price of the stock is -6.22% and the stock has fallen -0.11% in the past 1 week.
The stock has recorded a 20-day Moving Average of 3.21% and the 50-Day Moving Average is 15.26%.The 200 Day SMA reached 16.36% Bristol-Myers Squibb Company has dropped 20.91% during the last 3-month period . Year-to-Date the stock performance stands at -18.26%.
Bristol-Myers Squibb Company (BMY) : Average target price received by Bristol-Myers Squibb Company (BMY) is $66.69 with an expected standard deviation of $13.13. The most aggressive target on the stock is $100, whereas the most downbeat target is $48. 13 financial analysts are currently covering the stock.
Company shares have received an average consensus rating of Hold for the current week Bristol-Myers Squibb Company (NYSE:BMY): stock was range-bound between the intraday low of $55.53 and the intraday high of $56.41 after having opened at $56.22 on Fridays session. The stock finally closed in the red at $56.22, a loss of -0.66%. The stock remained in the red for the whole trading day. The total traded volume was 12,082,897 shares. The stock failed to cross $56.41 in Fridays trading. The stocks closing price on Thursday was $55.97.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products across the world. The Companys products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. The Company manufactures its products in the United States, Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers, such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print, radio, television, and digital advertising and promotion. In addition, the Company holds rights to F001287, which is a preclinical, small-molecule IDO1-inhibitor.